Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / PCOS Renamed Polyendocrine Metabolic...
Tech medical renaming

PCOS Renamed Polyendocrine Metabolic Ovarian Syndrome

Analysis based on 145 articles · First reported May 12, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
4
Articles
145
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The renaming of Polyendocrine metabolic ovarian syndrome (PMOS) is expected to positively impact the healthcare and pharmaceutical industries by driving more accurate diagnoses, personalized treatments, and increased research funding. This shift could lead to new product development and improved patient outcomes, potentially increasing demand for related medical services and pharmaceuticals. The change also aims to reduce stigma and improve patient understanding, which could lead to earlier interventions and better long-term health management.

healthcare pharmaceuticals medical research
Event Summary

Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting one in eight women globally, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, announced in The Lancet after 14 years of global collaboration led by Helena Teede of Monash University, aims to correct the previous misleading terminology. The old name, PCOS, oversimplified the condition by focusing on 'cysts' that are not true cysts and obscuring its complex hormonal and metabolic aspects. Experts like Melanie Cree and Anuja Dokras emphasize that PMOS better reflects the disorder's impact on weight, metabolic and mental health, the reproductive system, and skin. The renaming is supported by 56 patient and professional organizations, including the International Androgen Excess and Polycystic Ovary Syndrome Society, and is expected to improve diagnosis, treatment, and research funding, particularly from entities like the United States — National Institutes of Health. While some, like PCOS Challenge, express concerns about the transition, the new name is intended to reduce stigma, promote holistic care, and be fully implemented in international guidelines by 2028.

Key Actions
100 Pediatric Endocrine Society renamed syndrome
90 Helena Teede chaired steering group Polyendocrine metabolic ovarian syndrome
90 International Androgen Excess and Polycystic Ovary Syndrome Society led consensus
90 Pediatric Endocrine Society announced name change
90 Helena Teede led team
80 European Society of Endocrinology announced renaming
70 Pediatric Endocrine Society celebrated change Polyendocrine metabolic ovarian syndrome
70 Helena Teede led research
70 Melanie Cree authored article
60 International Androgen Excess and Polycystic Ovary Syndrome Society collaborated on renaming Polyendocrine metabolic ovarian syndrome
60 Terhi Piltonen wrote research letter
60 Helena Teede described condition
60 Anuja Dokras contributed to understanding
60 Robyn Vettese hopes for understanding
60 Jamie Benham aims to raise awareness
+ 9 more actions View on Dashboard
Entities Involved
oth
Polyendocrine metabolic ovarian syndrome
Polyendocrine metabolic ovarian syndrome, a common condition affecting women, has been renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its complex nature and improve diagnosis and treatment.
Importance 100 Sentiment 50
per
Helena Teede
Helena Teede, Director of Monash Centre for Health Research and Implementation, led the global initiative to rename Polyendocrine metabolic ovarian syndrome, advocating for a more accurate and comprehensive understanding of the condition.
Importance 95 Sentiment 80
ngo
International Androgen Excess and Polycystic Ovary Syndrome Society
The International Androgen Excess and Polycystic Ovary Syndrome Society played a key role in the global consensus process for renaming Polyendocrine metabolic ovarian syndrome, contributing to the research and advocacy efforts.
Importance 80 Sentiment 70
per
Terhi Piltonen
Terhi Piltonen, President of the International Androgen Excess and Polycystic Ovary Syndrome Society and lead author of The Lancet paper, co-led the name change process, emphasizing the need for scientific accuracy and cultural appropriateness.
Importance 75 Sentiment 60
per
Melanie Cree
Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz and an author of The Lancet article, supports the name change to Polyendocrine metabolic ovarian syndrome, hoping it will lead to better care and potential research funding.
Importance 70 Sentiment 60
per
Anuja Dokras
Anuja Dokras, Executive Director of the International Androgen Excess and Polycystic Ovary Syndrome Society and director of the Penn Polycystic Ovary Syndrome Center, was a senior author on The Lancet paper, highlighting the long-term cardiovascular and mental health effects of Polyendocrine metabolic ovarian syndrome.
Importance 70 Sentiment 60
per
Rachel Morman
Rachel Morman, Chair of Verity PCOS UK, was a lived experience expert in the global name change process, emphasizing that the new name better reflects the hormonal and metabolic dimensions of Polyendocrine metabolic ovarian syndrome.
Importance 60 Sentiment 50
cnt
India
India is experiencing a sharp rise in PMOS diagnoses, especially among urban adolescents and young women, making the name change particularly important for improving awareness and management.
Importance 60 Sentiment 0
ngo
Verity PCOS UK
Verity PCOS UK, represented by its Chair Rachel Morman, was involved in the global collaboration to rename Polyendocrine metabolic ovarian syndrome, advocating for patient perspectives.
Importance 50 Sentiment 50
ngo
World Health Organization
The World Health Organization estimates the prevalence of PMOS, highlighting the global impact and the need for improved diagnosis and care.
Importance 50 Sentiment 0
per
Thais Aliabadi
Thais Aliabadi, an OBGYN and cofounder of Ovii, supports the new name PMOS as it better reflects the whole-body nature of the condition.
Importance 50 Sentiment 20
per
Rohan Palshetkar
Rohan Palshetkar, an IVF and Fertility Specialist at Bloom IVF, explained that PCOS was an incomplete name and the new terminology will reduce fear and stigma.
Importance 50 Sentiment 20
per
Arun Mukka
Arun Mukka, a Senior Consultant Endocrinologist at Yashoda Hospitals, highlighted that PMOS is a broader metabolic and hormonal condition, not just an ovarian disorder.
Importance 50 Sentiment 20
per
Muskaan Chhabra
Muskaan Chhabra, a Fertility Specialist at Birla Fertility & IVF, believes the name change will broaden understanding beyond fertility concerns alone, especially for women in India.
Importance 50 Sentiment 20
per
M. V. Jyothsna
M. V. Jyothsna, a Consultant Obstetrician and Gynaecologist at Yashoda Hospitals, stated that the new terminology may improve awareness about long-term risks associated with the condition.
Importance 50 Sentiment 20
+ 53 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.